Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.47 |
| ▸ | REN | P00797 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091321 | 1.00 | ACE (0.47) | ACERENKDM4EF2LMNA | |
| SCHEMBL23091320 | 1.00 | ACE (0.47) | ACERENKDM4EF2LMNA | |
| SCHEMBL29379676 | 0.92 | ACE (0.54) | ACERENKDM4EF2LMNA | |
| SCHEMBL31547785 | 0.91 | ACE (0.53) | ACERENKDM4EF2LMNA | |
| SCHEMBL29434627 | 0.90 | CAPN1 (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL29371779 | 0.89 | ACE (0.48) | ACERENKDM4EF2LMNA | |
| SCHEMBL29722270 | 0.89 | ACE (0.48) | ACERENKDM4EF2LMNA | |
| SCHEMBL30522298 | 0.89 | CAPN1 (0.51) | ACERENKDM4EF2LMNA | |
| SCHEMBL29894803 | 0.88 | ACE (0.52) | ACERENKDM4EF2LMNA | |
| SCHEMBL30165187 | 0.88 | F2R (0.47) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ACE 930/4885REN 1894/4885KDM4E 300/4885 |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ACE 930/4885REN 1894/4885KDM4E 300/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ACE 930/4885REN 1894/4885KDM4E 300/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ACE 930/4885REN 1894/4885KDM4E 300/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | ACE 930/4885REN 1894/4885KDM4E 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.